Chiwai Chan, DO
Interventional Pain Medicine · Fountain Valley, CANPI 1629051529
Payments from drug & device makers
Across 33 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$185
- AbbVie$73
- Daiichi Sankyo Inc.$69
- Pfizer$65
- Novartis$61
- Scilex Pharmaceuticals Inc.$54
- plus $160 from 8 others
What the payments were for
- Food & beverage$667100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $185 |
| AbbVie(2 entities) | 3 | $73 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Pfizer | 4 | $65 |
| Novartis | 3 | $61 |
| Scilex Pharmaceuticals Inc. | 3 | $54 |
| Amgen | 1 | $33 |
| Valinor Pharma, LLC | 2 | $29 |
| Medtronic | 1 | $21 |
| Abbott | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Sentynl Therapeutics, Inc. | 1 | $12 |
How this compares
$667 in reported general payments places this provider in the 25th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 190 | $1,993 |
| Lidocaine | 13 | $1,472 |
| Oxycodone Hcl | 74 | $1,100 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 80 | $741 |
| Hydromorphone Hcl | 39 | $336 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $272 |
| Tizanidine Hcl | 20 | $241 |
| Pregabalin | 17 | $224 |
| Methadone Hcl | 26 | $204 |
| Gabapentin | 27 | $193 |
| Baclofen | 22 | $180 |
| Morphine Sulfate | 16 | $170 |
| RizatriptanRizatriptan Benzoate | 14 | $161 |
| Cyclobenzaprine Hcl | 11 | $146 |
| Diclofenac Sodium | 13 | $135 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Fountain Valley
- Howard DedesFountain Valley$17K
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.